CAR-T for Chronic Lymphocytic Leukemia Receives FDA Approval.

Published Date: 18 Mar 2024

For CLL/SLL patients who are refractory or have relapsed, lixocabtagene maraleucel (Breyanzi) has a new indication.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Study: For predicting breast cancer, AI performs better than traditional risk models.

2.

Maintenance Rituximab Improves Survival in Elderly MRD-Negative MCL Patients.

3.

Targeted radiation therapy shows near-complete response in rare sarcoma patients

4.

Chicken Broth Recall; Medicaid at Risk; Princess Kate Thanks Medical Staff

5.

Clinical trial could lead to new 'gold standard' test for prostate cancer detection


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot